CN1858067A - 自玉足海参中提取玉参多糖的方法,该玉参多糖及其药物用途 - Google Patents
自玉足海参中提取玉参多糖的方法,该玉参多糖及其药物用途 Download PDFInfo
- Publication number
- CN1858067A CN1858067A CN 200510067956 CN200510067956A CN1858067A CN 1858067 A CN1858067 A CN 1858067A CN 200510067956 CN200510067956 CN 200510067956 CN 200510067956 A CN200510067956 A CN 200510067956A CN 1858067 A CN1858067 A CN 1858067A
- Authority
- CN
- China
- Prior art keywords
- beautiful
- polysaccharide
- gracilis polysaccharide
- hojothuria
- leucosppilota
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 15
- 150000004676 glycans Chemical class 0.000 claims abstract description 82
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 82
- 239000005017 polysaccharide Substances 0.000 claims abstract description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 6
- 208000006011 Stroke Diseases 0.000 claims abstract description 6
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims abstract description 6
- 238000001556 precipitation Methods 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 208000028867 ischemia Diseases 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 208000005189 Embolism Diseases 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 101800000263 Acidic protein Proteins 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract description 13
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 11
- 230000004089 microcirculation Effects 0.000 abstract description 10
- 206010008118 cerebral infarction Diseases 0.000 abstract description 9
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 6
- 210000003446 pia mater Anatomy 0.000 abstract description 6
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 40
- 241001465754 Metazoa Species 0.000 description 19
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 238000003304 gavage Methods 0.000 description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 238000000465 moulding Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 8
- 230000035602 clotting Effects 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 241000251511 Holothuroidea Species 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 210000003194 forelimb Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000010977 jade Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 101800004637 Communis Proteins 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- IGQOJHALNKTFKX-UHFFFAOYSA-N N1C=CC=C1.N#CC#N Chemical class N1C=CC=C1.N#CC#N IGQOJHALNKTFKX-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004895 regional blood flow Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241000272165 Charadriidae Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001213462 Holothuria leucospilota Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | 动物数(只) | 行为评分 | ||
4 | 6 | 24(h) | |||
假手术模型对照玉参多糖玉参多糖玉参多糖阿斯匹林 | --0.5ml/100g50100200200 | 101010101010 | 0.5±0.47.8±4.1+++5.9±3.45.2±3.84.8±3.46.3±3.7 | 0.7±0.610.0±2.6+++6.3±3.6*5.5±4.0**4.1±3.5***5.0±2.8*** | 0.6±0.69.1±2.8+++5.2±2.8**3.2±3.0***2.8±1.5***2.9±2.0*** |
药物 | 剂量(mg/kg) | 动物数(只) | 梗塞范围(%) |
假手术模型对照玉参多糖玉参多糖玉参多糖阿斯匹林 | ---0.5ml/100g50100200200 | 101010101010 | 0.011.1±6.45.7±4.1*3.5±3.3**2.1±1.4***2.8±2.4** |
药物 | 剂量(mg/kg) | 造型前 | 造型后 | |||
15min | 30min | 45min | 60min | |||
溶剂对照玉参多糖玉参多糖玉参多糖天保宁 | --50100200200 | 38.8±4.0△35.7±4.1△38.3±5.8△38.3±6.6△38.8±4.8△ | 31.0±10-7.8±8.7*37.8±4.42.1±3.836.5±6.4-1.8±6.737.5±7.3-0.8±5.233.6±7.5-3.7±5.9 | 24.1±9.1-14.1±7.4**34.3±5.7**-1.4±6.834.3±4.5**-4.0±8.836.0±8.4**-2.3±3.932.6±7.8*-4.2±5.9 | 22.8±7.0-16.0±5.431.5±5.2**-4.2±7.136.4±6.8***-1.9±7.335.9±7.8***-2.4±5.331.6±8.4*-4.4±8.3 | 21.4±5.7-17.4±4.331.6±7.2**-4.1±8.337.8±8.6***-0.5±8.636.4±7.2***-1.9±3.733.5±7.0***-3.3±6.1 |
药物 | 剂量(mg/kg) | 造型前 | 造型后 | |||
15 | 30 | 45 | 60min | |||
溶剂对照玉参多糖天保宁 | --50100200200 | 5.3±0.5△5.6±0.5△5.6±0.6△5.4±0.4△5.3±0.5△ | 5.1±0.7-0.2±0.55.7±0.70.1±0.46.0±0.6**0.3±0.65.9±0.6*0.6±0.7#5.2±0.6-0.1±0.4 | 4.8±0.5-0.4±0.25.7±0.7**0.1±0.95.6±0.8*-0.1±0.85.8±0.8*0.4±0.85.2±0.70.1±0.6 | 4.7±0.5-0.5±0.45.6±0.6**-0±0.85.5±0.9*-0.2±0.85.9±0.7***0.4±0.95.1±0.6-0.2±0.4 | 4.8±0.7-0.5±0.65.7±1.0*-0.1±1.15.8±0.9*-0.1±0.65.8±0.7**0.4±0.85.2±0.60±0.5 |
药物 | 剂量(mg/kg) | 全血粘度 | |||
7.5s-1 | 18.8s-1 | 37.5s-1 | 75s-1 | ||
空白对照模型对照玉参多糖玉参多糖玉参多糖天保宁 | ----50100200200 | 4.77±1.5012.42±2.9+++9.42±2.23*7.56±1.10***7.08±1.01***#8.40±1.41*** | 4.21±0.947.01±1.51+++6.05±1.585.47±0.82*5.59±1.10**#6.84±1.49 | 3.91±0.996.12±1.14+++5.64±1.135.20±0.72*5.11±0.78**#6.18±1.14 | 3.42±0.855.45±0.97+++5.05±1.014.82±.574.72±0.925.45±1.02 |
药物 | 剂量(mg/kg) | 动物数(只) | 血栓形成时间(s) |
溶剂对照玉参多糖玉参多糖玉参多糖阿斯匹林 | --50100200200 | 1010101010 | 666±106758±133793±122*828±132**831±142** |
药物 | 剂量(mg/kg) | 动物数(只) | 血小板凝聚百分率(%) | ||
ADP | 花生四烯酸 | 胶原 |
溶剂对照玉参多糖玉参多糖玉参多糖阿斯匹林 | --50100200200 | 1010101010 | 51±1343±1535±15**32±9***39±11* | 64±1544±15**41±15***33±9***###10±5*** | 61±1050±9*49±18*38±12***45±14** |
药物 | 剂量(mg/kg) | 鼠数(只) | 凝血时间(min) |
溶剂对照玉参多糖玉参多糖玉参多糖阿斯匹林天保宁 | --200400800200200 | 101010101010 | 15′11″±7′24″20′37″±87′7″24′57″±11′3″*28′55″±10′42″**27′5″±12′9″*26′31″±11′29″* |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100679564A CN100432232C (zh) | 2005-04-30 | 2005-04-30 | 自玉足海参中提取玉参多糖的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100679564A CN100432232C (zh) | 2005-04-30 | 2005-04-30 | 自玉足海参中提取玉参多糖的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1858067A true CN1858067A (zh) | 2006-11-08 |
CN100432232C CN100432232C (zh) | 2008-11-12 |
Family
ID=37297027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100679564A Active CN100432232C (zh) | 2005-04-30 | 2005-04-30 | 自玉足海参中提取玉参多糖的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100432232C (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863997A (zh) * | 2010-05-24 | 2010-10-20 | 南京中医药大学 | 玉足海参多糖的制备方法 |
CN102028730A (zh) * | 2010-12-14 | 2011-04-27 | 大连海晏堂生物有限公司 | 一种海参复方制品、制法及其在使用中的剂型 |
WO2013131406A1 (zh) * | 2012-03-05 | 2013-09-12 | 上海开润生物医药有限公司 | 解聚海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
CN103788222A (zh) * | 2014-01-08 | 2014-05-14 | 中国科学院昆明植物研究所 | Fuc3S4S取代的低聚糖胺聚糖及其制备方法 |
US8927523B2 (en) | 2010-12-14 | 2015-01-06 | Dalian Haiyantang Biology Co., Ltd. | Compound sea cucumber preparation and manufacturing method thereof |
CN107536058A (zh) * | 2017-07-14 | 2018-01-05 | 宁波海博士特医食品科技有限公司 | 一种海参粘多糖的制造方法 |
CN110613832A (zh) * | 2019-10-31 | 2019-12-27 | 西安惠普生物科技有限公司 | 一种海参多肽在医疗器械的应用和制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1343729A (zh) * | 2000-09-20 | 2002-04-10 | 天津市贝特科技发展有限公司 | 甘草多糖 |
CN1334040A (zh) * | 2001-08-21 | 2002-02-06 | 曲世尧 | 一种海参系列产品及其加工方法 |
-
2005
- 2005-04-30 CN CNB2005100679564A patent/CN100432232C/zh active Active
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863997A (zh) * | 2010-05-24 | 2010-10-20 | 南京中医药大学 | 玉足海参多糖的制备方法 |
CN101863997B (zh) * | 2010-05-24 | 2012-05-23 | 南京中医药大学 | 玉足海参多糖的制备方法 |
CN102028730A (zh) * | 2010-12-14 | 2011-04-27 | 大连海晏堂生物有限公司 | 一种海参复方制品、制法及其在使用中的剂型 |
CN102028730B (zh) * | 2010-12-14 | 2012-07-04 | 大连海晏堂生物有限公司 | 一种海参复方制品、制法及其在使用中的剂型 |
US8927523B2 (en) | 2010-12-14 | 2015-01-06 | Dalian Haiyantang Biology Co., Ltd. | Compound sea cucumber preparation and manufacturing method thereof |
WO2013131406A1 (zh) * | 2012-03-05 | 2013-09-12 | 上海开润生物医药有限公司 | 解聚海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
US9539271B2 (en) | 2012-03-05 | 2017-01-10 | Shanghai Kairun Biology Medicine Limited Liability Company | Application of depolymerized holothurian glycosaminoglycans (DHG) in preparation of drug for prevention and treatment of thromboembolic diseases |
CN103788222A (zh) * | 2014-01-08 | 2014-05-14 | 中国科学院昆明植物研究所 | Fuc3S4S取代的低聚糖胺聚糖及其制备方法 |
CN103788222B (zh) * | 2014-01-08 | 2016-08-31 | 中国科学院昆明植物研究所 | Fuc3S4S取代的低聚糖胺聚糖及其制备方法 |
CN107536058A (zh) * | 2017-07-14 | 2018-01-05 | 宁波海博士特医食品科技有限公司 | 一种海参粘多糖的制造方法 |
CN110613832A (zh) * | 2019-10-31 | 2019-12-27 | 西安惠普生物科技有限公司 | 一种海参多肽在医疗器械的应用和制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100432232C (zh) | 2008-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1858067A (zh) | 自玉足海参中提取玉参多糖的方法,该玉参多糖及其药物用途 | |
CN102153668B (zh) | 一种抗癌的黄绿蜜环菌多糖及提取工艺 | |
CN104225609A (zh) | 一种炎症靶向的中性粒细胞递药系统及其应用 | |
Porwal et al. | A comprehensive study on different methods of extraction from guajava leaves for curing various health problem | |
CN102327541A (zh) | 强化蛇蜂纳米硒、锗元素胶囊 | |
CN111514231A (zh) | 一种麻杏宣肺中药组合物作为流感病毒治疗药物的应用 | |
CN1207022C (zh) | 促进骨折愈合和骨关节损伤修复的药物组合物及其制备方法和应用 | |
CN110301647A (zh) | 地龙蛋白复合低聚肽营养品 | |
CN103230018A (zh) | 蛇粉元素维生素保健胶囊 | |
CN106074643B (zh) | 红毛五加叶及其提取物在制备抗疲劳的药物或保健食品中的用途 | |
CN111514230A (zh) | 一种麻杏宣肺中药胶囊及其制备方法 | |
CN102389449B (zh) | 一种灯盏细辛提取物及其制备方法和应用 | |
CN115397263B (zh) | 一种包含n-乙酰氨基葡萄糖的组合物及其制备方法和应用 | |
CN103690539A (zh) | 钩吻素子及其同系物在制备治疗糖尿病并发症药物中的应用 | |
CN1899352A (zh) | 一种益气复脉的中药有效部位组合物 | |
CN107929381A (zh) | 一种通过饮水给药的连蒲双清散制作工艺 | |
CN1823884A (zh) | 一种艾迪注射制剂的制备方法 | |
CN106310216A (zh) | 吉林人参低聚肽在制备增强免疫力的食品或保健食品中的用途 | |
CN104666328A (zh) | 一种中药多糖在药物中的应用及其提取方法 | |
CN104208136A (zh) | 苦豆子碱奶牛乳房注入剂的制备工艺和使用方法 | |
CN101721510B (zh) | 治疗头痛或偏头痛的药物组合物及其制备方法 | |
CN104107210A (zh) | 一种抗疲劳微乳液及其制备方法 | |
CN1593645A (zh) | 一种抗癌药物及其制备方法 | |
CN102225173B (zh) | 一种治疗头痛的中药制剂及其制备方法 | |
CN1593574A (zh) | 治疗心脑血管疾病的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG HONGDOUSHAN MEDICINE CO., LTD. Free format text: FORMER OWNER: CHEN RENZHONG Effective date: 20080627 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080627 Address after: Heilongjiang yew Pharmaceutical Co., Ltd. No. 2 Wuyi Road, A Cheng Economic Development Zone, Heilongjiang Province, China: 150300 Applicant after: Heilongjiang Hongdoushan Pharmaceutical Co., Ltd. Address before: Jiangsu province Changzhou City Taiping Road Regency garden 11 C room unit 101 post encoding: 213003 Applicant before: Chen Renzhong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |